ERBB2 and breast carcinoma: According to a multicenter, retrospective study in China, in patients with HR‐positive/HER2‐negative advanced breast cancer who exhibited disease progression after palbociclib therapy, a CDK4/6 inhibitor, an increase of up to 5.1 months in median PFS was observed after receiving everolimus in combination with endocrine therapy [22].